文献速递免疫规划

评估一种增强猪繁殖与呼吸综合征病毒疫苗效力与易用性的策略

Evaluation of a strategy to enhance the efficacy and ease of application of porcine reproductive and respiratory syndrome virus vaccines.
PubMed 文献 · Vaccine · 2025-09-19

为应对现有猪繁殖与呼吸综合征病毒(PRRSV)疫苗免疫原性和效力欠佳及农场储存接种条件不规范问题,研究将45头4周龄PRRSV阴性仔猪分为5组,比较固体剂型MLV单独免疫及联合鼻腔灭活MLV加强的「prime and pull」策略与常规液体MLV肌注的效果。结果显示鼻腔灭活疫苗加强未能增强效力,而固体剂型疫苗诱导的中和抗体应答和保护效果与常规针筒注射MLV悬浮液相当。

要点

  • 固体剂型PRRSV-1 MLV诱导的中和抗体应答及保护效果与常规液体MLV肌注相当。
  • 鼻腔接种灭活MLV加强未能增强固体剂型MLV的效力。
  • 数据支持进一步开发固体剂型技术作为猪用PRRSV MLV等疫苗常规接种的实用替代方案。

核心结论

  • 固体剂型PRRSV-1 MLV提供的保护效果与常规针筒注射MLV悬浮液相当,鼻腔灭活疫苗加强未能增强效力,数据支持进一步开发固体剂型技术作为实用替代方案。

研究设计与样本

  • 45头4周龄PRRSV阴性仔猪分为5组:基准组10头肌注液体MLV,固体剂型MLV单独免疫组10头,固体剂型MLV初免后3周鼻腔接种灭活MLV加强组10头,未免疫攻毒对照组10头,未免疫未攻毒组5头。
  • 免疫后35天以PRRSV-1田间株攻毒,攻毒后10天剖检,用RT-qPCR检测病毒血症和鼻排毒,用ELISA和病毒中和试验检测血清和支气管肺泡灌洗液抗体应答。

主要发现

  • 鼻腔灭活疫苗加强未能增强效力。
  • 固体剂型疫苗提供中和抗体应答和保护效果(减少病毒血症、病毒排毒和肉眼肺病变),与标准针筒注射PRRSV MLV悬浮液相当。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Control of porcine reproductive and respiratory syndrome viruses (PRRSV) is sometimes hindered by the suboptimal immunogenicity and efficacy of existing vaccines. In addition, not following vaccine storage and administration conditions on-farm can negatively impact on the efficacy of current vaccines and present barriers to the development of more efficacious vaccination strategies. To address these challenges, we evaluated whether a 'prime and pull' immunisation strategy combining a prime with a 'needle-free' solid dose formulation of modified live PRRSV-1 vaccine (MLV), and a nasal boost with inactivated PRRSV-1 administered by an automated jet device can enhance protection against challenge infection. Forty-five, 4-week-old, PRRSV naïve, piglets were divided into 5 groups; including a benchmark group (10 pigs, vaccinated with a liquid MLV delivered by intramuscular injection), a prime only group (10 pigs vaccinated with the solid dose MLV), a prime/pull group (10 pigs vaccinated with the solid dose MLV and boosted 3 weeks later by nasal inoculation with inactivated MLV), an unvaccinated challenge control group (10 pigs) and a naïve group (5 pigs, without vaccination and PRRSV challenge). Pigs were challenged with a PRRSV-1 field strain 35 days post-vaccination and necropsied 10 days post-challenge. PRRSV viremia and nasal shedding were inferred by RT-qPCR, and antibody responses were assessed in serum and bronchoalveolar lavage by ELISA and virus neutralisation test. Whilst the nasal inactivated vaccine boost failed to augment efficacy, the solid dose vaccine provided neutralising antibody responses and protection (reduced viremia, virus shedding and gross lung lesions) comparable to the standard needle and syringe inoculation of PRRSV MLV suspension. These data support the further development of the solid dose formulation technology as a practical alternative to conventional delivery of PRRSV MLV and other vaccines to pigs.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Schiavone A, Edwards JC, Vigneswaran E, et al. Evaluation of a strategy to enhance the efficacy and ease of application of porcine reproductive and respiratory syndrome virus vaccines. Vaccine. 2025. PMID: 40974733. doi:10.1016/j.vaccine.2025.127757

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。